HC Wainwright Weighs in on Omeros’ Q1 Earnings (NASDAQ:OMER)

Omeros Corporation (NASDAQ:OMER) – HC Wainwright lifted their Q1 2026 earnings per share (EPS) estimates for Omeros in a research report issued on Wednesday, April 1st. HC Wainwright analyst B. Folkes now expects that the biopharmaceutical company will post earnings per share of ($0.40) for the quarter, up from their prior forecast of ($0.59). HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Omeros’ current full-year earnings is ($3.09) per share. HC Wainwright also issued estimates for Omeros’ Q2 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.39) EPS, Q4 2026 earnings at ($0.36) EPS, FY2026 earnings at ($1.54) EPS, FY2027 earnings at ($0.08) EPS, FY2028 earnings at $2.05 EPS, FY2029 earnings at $4.06 EPS and FY2030 earnings at $5.23 EPS.

A number of other research firms also recently weighed in on OMER. Wall Street Zen raised shares of Omeros from a “sell” rating to a “hold” rating in a research report on Saturday. D. Boral Capital restated a “buy” rating and issued a $36.00 price target on shares of Omeros in a research report on Tuesday, January 27th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Omeros in a research note on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.33.

Omeros Price Performance

Shares of Omeros stock opened at $10.90 on Friday. The business has a fifty day simple moving average of $11.36 and a two-hundred day simple moving average of $9.87. The company has a market capitalization of $784.80 million, a price-to-earnings ratio of -21.80 and a beta of 2.53. Omeros has a 1 year low of $2.95 and a 1 year high of $17.65.

Omeros (NASDAQ:OMER) last posted its earnings results on Tuesday, March 31st. The biopharmaceutical company reported $3.14 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $3.69.

Hedge Funds Weigh In On Omeros

Institutional investors have recently added to or reduced their stakes in the business. Newbridge Financial Services Group Inc. bought a new stake in shares of Omeros in the 2nd quarter valued at $280,000. Russell Investments Group Ltd. lifted its position in shares of Omeros by 113.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 5,677 shares during the period. Sei Investments Co. bought a new position in Omeros during the second quarter worth $40,000. Tower Research Capital LLC TRC grew its holdings in Omeros by 829.6% in the second quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 11,971 shares during the period. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in Omeros in the fourth quarter worth $33,000. 48.79% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Omeros

In related news, CAO David J. Borges sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $12.31, for a total transaction of $369,300.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 12.90% of the stock is currently owned by insiders.

Key Omeros News

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: Omeros says it has reached a profitability milestone as part of a strategic shift toward commercialization and partnerships, which management says should improve cash flow and de-risk the business. Omeros Reaches Profitability Milestone Amid Strategic Shift
• Positive Sentiment: HC Wainwright raised near-term EPS estimates for multiple 2026 quarters and lifted FY2026/FY2027 forecasts, while keeping a Buy rating and a $40 price target — a bullish analyst stance that supports higher share valuations. HC Wainwright raises estimates and reiterates Buy, $40 PT
• Positive Sentiment: Q4 results were stronger than expected (company-reported EPS beat and a licensing/deal with Novo Nordisk cited as boosting Q4), providing immediate revenue/earnings proof points that likely pushed the stock higher. Omeros rises as Novo deal boosts Q4 earnings
• Positive Sentiment: Unusually large call-option purchases were reported, signaling bullish positioning by traders and adding short-term upside pressure. Traders Purchase Large Volume of Call Options on Omeros
• Neutral Sentiment: Several analyst and market-commentary pieces outline the bull case ahead of Q1 commercial updates and provide earnings-call detail — useful for context but not immediate catalysts on their own. Omeros: Making The Bull Case On Q4 Earnings
• Neutral Sentiment: Earnings call transcript and summaries are available for deeper detail on guidance and commercialization plans; these will matter when management discusses Q1 commercial progress. Q4 2025 Earnings Call Transcript
• Negative Sentiment: HC Wainwright trimmed several longer-term EPS estimates (FY2028–FY2030), lowering some multi-year upside expectations — a signal that while near-term outlook improved, longer-term model risk remains. HC Wainwright trims long-term EPS forecasts

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.